492 related articles for article (PubMed ID: 21271945)
1. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Doi A; Shimada T; Harada S; Iwata K; Kamiya T
Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
4. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
5. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria.
Fong JJ; Rosé L; Radigan EA
Ann Pharmacother; 2012 Mar; 46(3):347-52. PubMed ID: 22395250
[TBL] [Abstract][Full Text] [Related]
7. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
Wells WG; Woods GL; Jiang Q; Gesser RM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
[TBL] [Abstract][Full Text] [Related]
8. [Urinary Tract Infections Caused by Community-Acquired Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in a Level III Hospital - A Retrospective Study].
Simões A; Lima M; Brett A; Queiroz C; Chaves C; Oliveira H; Januário L; Rodrigues F
Acta Med Port; 2020 Jul; 33(7-8):466-474. PubMed ID: 31962058
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
Vardi M; Kochavi T; Denekamp Y; Bitterman H
Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
11. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
[TBL] [Abstract][Full Text] [Related]
12. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
14. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
15. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
[TBL] [Abstract][Full Text] [Related]
16. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
Teng CP; Chen HH; Chan J; Lye DC
Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
[TBL] [Abstract][Full Text] [Related]
17. Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study.
Dayan N; Dabbah H; Weissman I; Aga I; Even L; Glikman D
J Pediatr; 2013 Nov; 163(5):1417-21. PubMed ID: 23919903
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in children.
Katsuta T; Shoji K; Watanabe Y; Saitoh A
Pediatr Infect Dis J; 2013 Apr; 32(4):417-9. PubMed ID: 23274920
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
[TBL] [Abstract][Full Text] [Related]
20. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
